P

Porton Pharma Solutions Ltd
SZSE:300363

Watchlist Manager
Porton Pharma Solutions Ltd
SZSE:300363
Watchlist
Price: 17.2 CNY -5.29% Market Closed
Market Cap: 9.4B CNY
Have any thoughts about
Porton Pharma Solutions Ltd?
Write Note

Porton Pharma Solutions Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Porton Pharma Solutions Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
P
Porton Pharma Solutions Ltd
SZSE:300363
Cash & Cash Equivalents
ÂĄ1.5B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
23%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash & Cash Equivalents
ÂĄ22.4B
CAGR 3-Years
74%
CAGR 5-Years
103%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash & Cash Equivalents
ÂĄ8.8B
CAGR 3-Years
59%
CAGR 5-Years
21%
CAGR 10-Years
24%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash & Cash Equivalents
ÂĄ22.3B
CAGR 3-Years
16%
CAGR 5-Years
41%
CAGR 10-Years
22%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash & Cash Equivalents
ÂĄ14.1B
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
21%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash & Cash Equivalents
ÂĄ391.7m
CAGR 3-Years
105%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Porton Pharma Solutions Ltd
Glance View

Market Cap
9.4B CNY
Industry
Pharmaceuticals

Porton Pharma Solutions Ltd. engages in the research and development and manufacture of pharmaceutical products and active pharmaceutical ingredients. The company is headquartered in Chongqing, Chongqing and currently employs 3,782 full-time employees. The company went IPO on 2014-01-29. The firm is also engaged in the multi-client product manufacturing businesses and pharmaceutical and chemical commerce businesses. The products of the Company include anti-viral, anti-diabetic, hypolipidemic, anti-cancer, anesthesia analgesia and anti-bacterial pharmaceuticals, among others. The firm operates its businesses in Europe, North America, Asia and China, among others.

Intrinsic Value
20.26 CNY
Undervaluation 15%
Intrinsic Value
Price
P

See Also

What is Porton Pharma Solutions Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
1.5B CNY

Based on the financial report for Sep 30, 2024, Porton Pharma Solutions Ltd's Cash & Cash Equivalents amounts to 1.5B CNY.

What is Porton Pharma Solutions Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
23%

Over the last year, the Cash & Cash Equivalents growth was -65%. The average annual Cash & Cash Equivalents growth rates for Porton Pharma Solutions Ltd have been 4% over the past three years , 3% over the past five years , and 23% over the past ten years .

Back to Top